SHR-1707

SHR-1707 is Shanghai Hengrui Pharmaceutical's anti-amyloid beta monoclonal antibody for mild cognitive impairment (MCI) and mild Alzheimer's disease - a follow-the-leader play against lecanemab (Leqembi) and donanemab (Kisunla), the two anti-Aβ antibodies that won FDA approval in 2023 and 2024 [1][2]. The program cleared multiple Phase 1 trials (healthy volunteers and patients) showing dose-dependent plasma Aβ reduction [3]. The Phase 2 pharmacodynamic study (NCT06199037) was registered but is listed as TERMINATED on ClinicalTrials.gov, which is a significant red flag the company has not publicly explained [4]. The competitive picture also got harder in October 2024 when Leqembi's subcutaneous formulation received FDA approval, removing the twice-monthly IV infusion burden that had been the dominant uptake friction [11]. For investors and watchers of the amyloid space, the question is whether Hengrui kills the program, pivots to a China-NMPA Phase 3, or restarts with a different design - and whether class economics support yet another IV-only anti-Aβ entrant given soft early commercial uptake and a now-SC-capable lead competitor.

Novel compound, never approved anywhere. Phase 1 development is well-documented: NCT04745104 (Hengrui-sponsored, n=50) and NCT04973189 (Hengrui-sponsored, n=63) ran single-ascending-dose safety and PK in healthy young and elderly adults, with the published Phase 1 readout in Alzheimer's Research & Therapy 2024 showing acceptable tolerability and dose-proportional pharmacokinetics with reductions in plasma Aβ40 and Aβ42 [3][5][6]. NCT05681819 (n=33) extended this into actual MCI/mild-AD patients and is marked completed [7]. A separate Australian-sponsored Phase 1 (NCT06114745, Atridia Pty Ltd, n=2) is also listed completed but the tiny enrollment is consistent with a bridging or PK study rather than a meaningful efficacy signal [8]. No FDA breakthrough, fast track, or orphan designations have been disclosed - this is being run primarily as a China-NMPA program, not a US-first development. The Phase 2 NCT06199037, registered as a safety/tolerability/pharmacodynamics study in mild AD, is currently flagged TERMINATED on CT.gov [4]. Hengrui has not issued a press release explaining the termination, and the CT.gov record itself provides no 'why' field entry beyond the status flag, so any inference about futility versus strategic deprioritization is speculative. There is no public Phase 3 timeline. Anyone modeling this asset should treat the Phase 2 status as the dominant uncertainty.

Alzheimer's brains accumulate sticky clumps of a small protein fragment called beta-amyloid (Aβ) outside neurons, and tangles of a different protein (tau) inside them. The amyloid hypothesis says: clear the plaques, slow the disease. SHR-1707 is an IgG antibody that binds Aβ and recruits the brain's immune cells (microglia) to phagocytose - eat - the aggregates [3]. Critically, the published Phase 1 paper does not clearly establish SHR-1707's structural binding preference (Aβ monomers vs. soluble oligomers/protofibrils vs. insoluble fibrillar plaques). This matters: lecanemab's protofibril selectivity was the scientific rationale for its differentiation over aducanumab, which targeted aggregated plaques and was eventually withdrawn from the US market in January 2024 [12]. Without a published epitope characterization, the writeup cannot say whether SHR-1707 is mechanistically equivalent to lecanemab, donanemab (plaque-selective), or something else - and the absence of that disclosure is itself a flag. The target gene is APP, which encodes the precursor protein that gets cleaved into Aβ; Open Targets gives APP a 0.80 evidence score for Alzheimer's, among the highest target-disease links in neurology. The mechanism is class-validated, not speculatively so: lecanemab slowed cognitive decline by 27% on CDR-SB over 18 months in CLARITY-AD [1], and donanemab showed 35% slowing in TRAILBLAZER-ALZ 2 [2]. CDR-SB (Clinical Dementia Rating-Sum of Boxes) scores patients 0-18, where higher scores mean worse function; a typical mild-AD patient worsens by about 1-1.5 points per year, so lecanemab's ≈0.45-point absolute difference is roughly a 4-6 month delay in disease progression. Patients and clinicians debate whether that magnitude is clinically meaningful, and the field is moving toward earlier intervention and combination with anti-tau approaches. SHR-1707 inherits both the upside and the ceiling of this class.

The Phase 2 trial that anchors this node is NCT06199037 - a study designed to evaluate safety, tolerability, and pharmacodynamics of IV SHR-1707 in patients with MCI due to Alzheimer's or mild Alzheimer's disease [4]. It was structured as a PD-focused study, not a cognition-endpoint study, which is typical for early dose-finding in this class. The trial is listed as TERMINATED on ClinicalTrials.gov with no public reason given [4]. That's the headline. The completed Phase 1 program is more informative: Yang et al. 2024 in Alzheimer's Research & Therapy reported results from two randomized, double-blind, single-ascending-dose Phase 1 studies in healthy adults showing the antibody was well tolerated across the dose range tested, with no ARIA - amyloid-related imaging abnormalities, the brain-swelling/microbleed signal that defines this class - reported in healthy volunteers [3]. The Phase 1 in actual AD patients (NCT05681819, n=33) is the critical ARIA dataset because the safety signal lives in amyloid-burdened brains, not healthy ones - but full results have not been published as of this writing, and until Hengrui reports ARIA rates in the target population the patient-relevant safety profile is unknown. APOE4 stratification is also unaddressed: ARIA-E rates run 2-3x higher in APOE4 carriers in the lecanemab and donanemab key trials, and both programs used genotyping to manage or exclude high-risk patients [1][2]. SHR-1707's enrollment strategy on APOE4 status has not been publicly described. Without a functional Phase 2 dataset, with the registered Phase 2 terminated, and with patient-population ARIA and APOE4 data unpublished, there is no efficacy or biomarker readout to evaluate. Until Hengrui restarts or clarifies, the trial-design picture is essentially a gap.

The model gives this drug a 4% chance of eventually being approved. That number starts from the typical approval rate for Phase 2 drugs in this area-about 24%-and is then adjusted using ten facts about the trial and its sponsor. The estimate is helped by more secondary endpoints than usual, and pulled down by heavier-than-usual blinding, a thin or weak sponsor approval record, and weak or limited earlier-phase results. The remaining facts were close to average for this stage, so they did not shift the estimate much.

Five concrete failure modes. (1) Program risk: NCT06199037 is terminated and the company has not publicly explained why. Sponsor-side terminations in oncology and CNS most often signal futility on PD/biomarker endpoints, safety, or strategic deprioritization - none of which are good [4]. (2) Safety: ARIA-E (edema) and ARIA-H (microhemorrhage) are class effects driven by the antibody pulling vascular amyloid; lecanemab carries a boxed warning and donanemab's TRAILBLAZER-ALZ 2 reported ARIA-E in 24% of treated patients with three deaths in the active arm linked to ARIA, with APOE4 homozygotes at materially higher risk [2]. SHR-1707's Phase 1 in healthy adults showed no ARIA but the relevant dataset is patients with cerebral amyloid burden, where the risk lives - and that dataset (NCT05681819) is unpublished. (3) Commercial: Leqembi global net sales were ~¥13B (~$87M) in Eisai's H1 FY2025 (April-September 2024), reflecting slow US uptake driven by twice-monthly IV infusions, MRI monitoring requirements, and CMS coverage friction [10]. Aducanumab was voluntarily withdrawn from the US market in January 2024 after commercial failure and a contested approval, which is the cautionary precedent for any me-too anti-Aβ entrant [12]. Most importantly, Leqembi SC was approved by FDA in October 2024 for monthly maintenance dosing, removing the infusion burden that was the primary stated objection from payers and patients - an IV-only anti-Aβ entry now faces an even steeper US commercial path [11]. (4) Sponsor: Hengrui's CNS biologics track record is thin compared to its oncology franchise, and the company has not signaled a US Phase 3 partnership - which is what an anti-Aβ program needs to be commercially relevant outside China. (5) Mechanism differentiation: without published binding-epitope data, there is no way to assess whether SHR-1707 has lecanemab-style protofibril selectivity, aducanumab-style plaque selectivity, or something else - and a me-too IV antibody with no disclosed mechanistic edge has a thin commercial thesis.

Low-priority watch. The terminated Phase 2 status is the dominant fact about this asset right now, and until Hengrui issues a clarifying statement - a restart, a redesign, an out-licensing deal, or a quiet program death - there is nothing to model. The specific data point that would convert this from noise to signal: a Hengrui or partner press release explaining NCT06199037's termination AND announcing a new Phase 2 with a defined PD endpoint, an APOE4 stratification plan, and an ARIA monitoring protocol. Absent that, check back in roughly six months. The broader read for BioCosm readers is that the anti-Aβ class is in an awkward middle phase - mechanism validated, commercial outcomes underwhelming, aducanumab withdrawn, and the next wave (subcutaneous administration, combination with anti-tau, earlier-intervention preclinical AD) is where the meaningful differentiation will come from. Leqembi SC's October 2024 approval already shifted the competitive bar, and an IV-only mild-AD entry is not differentiated against it. The genuinely interesting Hengrui story to track is not this molecule's US prospects but whether the company commits real capital to a China-NMPA anti-Aβ position. The Chinese AD market has different dynamics - much larger prevalent population, limited amyloid-PET infrastructure for diagnostic confirmation, NRDL (National Reimbursement Drug List) pricing pressure that would force a much lower price point than US Leqembi, and a regulatory regime that has been increasingly willing to approve domestic biologics on Chinese key data alone. The same molecule could have a very different commercial outcome inside that envelope, and that is where the SHR-1707 narrative is most likely to actually matter.